Rezpeg now carries the Nektar story
- Rezpegaldesleukin, or REZPEG, is the lead asset and now drives most of the investment case.
- Nektar started the ZENITH-AD Phase 3 program in July 2026, with first topline data expected in mid-2028.
- The company reached an FDA agreement on a single registrational Phase 3 trial for alopecia areata planned for early 2027.
- Nektar held $1.02 billion in cash and investments at the end of the second quarter of 2026.
- A key jury trial in the Eli Lilly lawsuit is scheduled in federal court for September 8th.
- The stock asks investors to pay today for a drug that may not reach the FDA before 2029.
A Phase 3 bet on immune reset
Nektar is now mostly a bet on REZPEG. The drug is designed to boost regulatory T cells, which are immune cells that help calm the body when the immune system is overactive. In atopic dermatitis, a serious form of eczema, Phase 2b data showed meaningful skin improvement and durability on less frequent dosing.
The bull case is clear. Nektar has started ZENITH-AD, a global Phase 3 program in moderate-to-severe atopic dermatitis. The company says first topline Phase 3 data are expected in mid-2028, with a planned FDA biologics license application in 2029 if the data work. REZPEG also showed statistically significant improvement in asthma control scores among atopic dermatitis patients with asthma, which could matter because DUPIXENT is one of the few drugs known for helping across related allergic diseases.
Alopecia areata adds upside with a newly clarified path. After an end-of-Phase 2 meeting, Nektar reached FDA alignment on a single 850-patient registrational Phase 3 study named ZENITH-AA. The company plans to start this trial in early 2027.
The bear case is timing and competition. Nektar must run large trials, compete with well-known biologics, and convince doctors to switch or add a new immune approach. The balance sheet gives it time, but the valuation score is weak because investors are being asked to price in success years before any possible commercial launch.
Cash funds trials, not sales
Nektar does not yet have a normal product-sales business. It is a clinical-stage research company, so its value comes from drug candidates moving through trials and, later, possible approvals or partnerships. Today, the key spending need is Phase 3 development for REZPEG.
The company regained full rights to REZPEG after Eli Lilly ended their collaboration. That gives Nektar more control and more upside if the drug works, but it also means Nektar must carry more of the cost and execution risk itself.
The funding picture is currently stable. Nektar ended the second quarter of 2026 with $1.02 billion in cash and investments. Management expects to end 2026 with $815 million to $840 million in cash. This extends the financial runway into the third quarter of 2028.
That cash cushion lowers near-term financing risk, but it came through heavy equity issuance over the prior year. Existing shareholders were diluted. The main business question is whether the upcoming data can create enough value to justify that dilution.
One lead drug, several shots
REZPEG in atopic dermatitis
This is Nektar's main program. ZENITH-AD started in July 2026 and is expected to produce first topline data in mid-2028.
REZPEG in alopecia areata
Nektar aligned with the FDA on a single Phase 3 trial design. The company plans to start ZENITH-AA in early 2027.
REZPEG in new onset type 1 diabetes
TrialNet is running a Phase 2 study in new onset stage 3 type 1 diabetes. Nektar supplies the drug and keeps rights to REZPEG.
NKTR-255
NKTR-255 is the lead oncology candidate. It gives Nektar a cancer immunotherapy option, but the current stock story is much more tied to REZPEG.
NKTR-0165 and NKTR-0166
These are early-stage autoimmune pipeline candidates. They may matter later, but they do not yet carry the same weight as REZPEG.
No real sales mix yet
Nektar reports as a clinical-stage research business, not as a company with commercial revenue segments. The mix shown below is a pipeline bucket view from the 2025 Form 10-K named programs, not a revenue split.
What can break the case
ZENITH-AD fails or looks too ordinary
High impact · Medium oddsThe main value driver is REZPEG in atopic dermatitis. If Phase 3 does not confirm the Phase 2b benefit, or if safety looks worse in larger trials, the stock thesis would change fast. Even a positive trial could disappoint if the effect does not look strong enough versus established drugs.
Doctors stay with entrenched biologics
High impact · Medium oddsDUPIXENT is already a major atopic dermatitis drug and has a strong position with doctors. REZPEG may need to prove durability, convenient dosing, and benefit in related conditions like asthma to win share. A new mechanism alone is not enough if doctors see no clear reason to switch.
Alopecia areata execution risks
Medium impact · Medium oddsWhile the FDA agreed to a single registrational Phase 3 trial for alopecia areata, the drug still has a mixed track record in this indication after missing the primary endpoint in a prior study. The trial could fail to replicate the later extension data.
Litigation becomes a bigger drag
Medium impact · Medium oddsNektar is in litigation with Eli Lilly over the ended REZPEG collaboration, with a jury trial scheduled for September 8th. It also faces a putative class action filed in March 2026. Legal cases may not decide the science, but they can add cost, distraction, and headline risk.
Cash runs out before approval
High impact · Low oddsThe latest capital raises lowered near-term funding risk, with runway into the third quarter of 2028. That still may not cover a full path to launch if trials expand, data are delayed, or approval takes longer than planned. More financing could dilute shareholders again.
In one breath
What does Nektar Therapeutics do?
Nektar develops medicines that change how the immune system acts. Its lead drug, REZPEG, is being tested mainly for autoimmune diseases such as atopic dermatitis and alopecia areata.
Why is REZPEG important for NKTR stock?
REZPEG is the center of the company story. If Phase 3 atopic dermatitis data are strong, Nektar could have a valuable new biologic, but weak data would hurt the thesis.
When could Nektar have Phase 3 data?
Nektar expects first topline data from the ZENITH-AD Phase 3 program in mid-2028. If the results support approval, the company is targeting a biologics license application in 2029.
Is Nektar profitable now?
No. Nektar is a clinical-stage biotech, so it is spending cash to run trials rather than earning steady product revenue.
Sources and research notes
This page combines Finn's company research with public filings and other cited materials. The thesis is reviewed when material company information changes; Finn Scores use the latest available scoring data.
- Thesis reviewed
- August 30, 2026
- Score data
- September 6, 2026
- Reviewed by
- Shivam Bharuka
Comparable Biotechnology companies
Companies near Nektar Therapeutics in Finn's Biotechnology industry ranking.
